Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [10][14]. Core Insights - The company has shown stable growth in its core pharmaceutical distribution business, achieving a revenue of 151.81 billion yuan in 2024, reflecting a year-on-year increase of 1.11%. The net profit attributable to shareholders reached 2.507 billion yuan, up by 15.33% [3][6]. - The successful issuance of public REITs has significantly contributed to the company's net profit, adding 576 million yuan in 2024 and 438 million yuan in Q1 2025 [4][9]. - The company is pioneering a dual listing platform in the pharmaceutical industry, combining equity and asset listings, which enhances its asset liquidity and sets a benchmark for the industry [7][9]. Financial Performance Summary - For 2024, the company reported an operating income of 151.81 billion yuan, with a net profit of 2.507 billion yuan. The operating cash flow was 3.083 billion yuan, although it saw a decline of 35.07% year-on-year [3][5]. - In Q1 2025, the company achieved an operating income of 42.016 billion yuan, a 3.82% increase, and a net profit of 970 million yuan, which is an impressive growth of 80.38% compared to the previous year [4][10]. - The company’s gross margin for 2024 was 7.80%, with a net profit margin of 1.65%. In Q1 2025, the gross margin slightly decreased to 7.33%, while the net profit margin improved to 2.31% [4][5]. Growth Projections - The company is expected to continue its growth trajectory, with projected revenues of 162.65 billion yuan, 174.30 billion yuan, and 186.62 billion yuan for 2025, 2026, and 2027 respectively. The net profit is forecasted to reach 3.010 billion yuan in 2025, growing to 3.458 billion yuan by 2027 [10][12].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [10][14]. Core Insights - The company has shown stable growth in its core pharmaceutical distribution business, achieving a revenue of 151.81 billion yuan in 2024, reflecting a year-on-year increase of 1.11%. The net profit attributable to shareholders reached 2.507 billion yuan, up by 15.33% [3][6]. - The successful issuance of public REITs has significantly contributed to the company's net profit, adding 576 million yuan in 2024 and 438 million yuan in Q1 2025 [4][9]. - The company is pioneering a dual listing platform in the pharmaceutical industry, combining equity and asset listings, which enhances its asset liquidity and sets a benchmark for the industry [7][9]. Financial Performance Summary - For 2024, the company reported an operating income of 151.81 billion yuan, with a net profit of 2.507 billion yuan. The operating cash flow was 3.083 billion yuan, showing a decline of 35% year-on-year due to increased payments to core suppliers [3][5][10]. - The first quarter of 2025 saw an operating income of 42.016 billion yuan, a 3.82% increase, and a net profit of 970 million yuan, marking an 80.38% rise compared to the previous year [4][10]. - The company’s gross margin for 2024 was 7.80%, with a net profit margin of 1.65%. In Q1 2025, the gross margin slightly decreased to 7.33%, while the net profit margin improved to 2.31% [4][5]. Growth Projections - The company is expected to achieve revenues of 162.65 billion yuan, 174.30 billion yuan, and 186.62 billion yuan for the years 2025, 2026, and 2027, respectively. The net profit attributable to shareholders is projected to be 3.010 billion yuan, 3.212 billion yuan, and 3.458 billion yuan for the same years [10][12]. - The report anticipates a steady growth rate of approximately 7% for the upcoming years, with a corresponding increase in earnings per share [10][12].

Group 1 - The core viewpoint of the news is that Jiuzhoutong has successfully established itself as a leader in the pharmaceutical logistics sector by launching the first public REITs and Pre-REITs fund in China, enhancing its asset management capabilities and market value [1][2] - Jiuzhoutong's 2024 revenue reached 151.81 billion yuan, with a net profit attributable to shareholders of 2.507 billion yuan, reflecting a year-on-year revenue growth of 2.58% and a net profit growth of 39.88% after adjusting for seasonal factors [2] - In Q1 2025, Jiuzhoutong reported a revenue of 42.016 billion yuan, a 3.82% increase year-on-year, and a net profit of approximately 970 million yuan, marking an 80.38% increase compared to the same period last year [2] Group 2 - The issuance of public REITs is a significant part of Jiuzhoutong's strategic transformation, aimed at revitalizing its pharmaceutical logistics assets and facilitating rapid business growth [1] - Jiuzhoutong has become the first company in the pharmaceutical industry to establish a dual listing platform of "equity + assets," setting a benchmark for asset management in the pharmaceutical distribution sector [1]